Silence Therapeutics PLC
SLN6.020USD
-0.150-2.43%
交易中 （美東）報價延遲15分鐘
852.98M總市值
虧損本益比TTM
關於 Silence Therapeutics PLC 公司
Silence Therapeutics plc 是一家總部位於英國的生物技術公司。該公司利用人體的天然 RNA 干擾 (RNAi) 機制來抑制特定靶基因的表達，從而開發藥物。該公司的 mRNAi GOLD（GalNAc 寡核苷酸發現）平臺可用於創建 siRNA（短干擾 RNA），精確靶向和沉默肝臟中的疾病相關基因。其全資擁有的候選產品包括 zerlasiran (SLN360)，旨在滿足降低出生時高脂蛋白 (a) 水平人羣心血管風險這一普遍存在的未滿足醫療需求，以及 SLN124，旨在治療血液病。該公司還與阿斯利康、Mallinckrodt Pharmaceuticals 和 Hansoh Pharma 等公司保持持續的研發合作。這些合作總共代表了多達 16 個管道項目。其其他在研產品包括SLN-HAN-1和SLN-HAN-2。
公司簡介
公司代碼SLN
公司名稱Silence Therapeutics PLC
上市日期Jan 05, 2010
CEOMr. Craig A. Tooman
員工數量116
證券類型Depository Receipt
年結日Jan 05
公司地址72 Hammersmith Road
城市LONDON
上市交易所NASDAQ Global Market Consolidated
國家United Kingdom
郵編W14 8TH
電話442034576900
網址https://www.silence-therapeutics.com/
公司代碼SLN
上市日期Jan 05, 2010
CEOMr. Craig A. Tooman
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
暫無數據
地區USD
名稱
營收
佔比
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
持股股東
持股股東
佔比
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
股東類型
持股股東
佔比
Individual Investor
24.38%
Investment Advisor
18.47%
Investment Advisor/Hedge Fund
10.53%
Hedge Fund
7.10%
Research Firm
5.08%
Venture Capital
3.35%
Private Equity
2.43%
Other
28.65%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
130
33.69M
71.34%
-14.09M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
2023Q2
54
31.78M
89.08%
+2.79M
2023Q1
52
31.17M
88.54%
+2.74M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.79M
5.91%
-41.94K
-1.48%
Mar 31, 2025
Redmile Group, LLC
2.21M
4.69%
-184.37K
-7.68%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.90M
4.01%
+333.48K
+21.34%
Mar 31, 2025
Lombard Odier Asset Management (USA) Corp.
1.85M
3.92%
-6.29K
-0.34%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.15M
2.43%
--
--
Mar 31, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
-7.25K
-0.69%
Mar 31, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.01%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.93%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
iShares Biotechnology ETF
佔比0.01%
SPDR S&P International Small Cap ETF
佔比0.01%
ActivePassive International Equity ETF
佔比0%
Tema Heart & Health ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
